Trilogy Capital Inc. Abb Vie Inc. Transaction History
Trilogy Capital Inc.
- $1.81 Billion
- Q2 2024
A detailed history of Trilogy Capital Inc. transactions in Abb Vie Inc. stock. As of the latest transaction made, Trilogy Capital Inc. holds 4,694 shares of ABBV stock, worth $926,971. This represents 0.04% of its overall portfolio holdings.
Number of Shares
4,694
Previous 4,767
1.53%
Holding current value
$926,971
Previous $868,000
7.26%
% of portfolio
0.04%
Previous 0.05%
Shares
27 transactions
Others Institutions Holding ABBV
# of Institutions
3,695Shares Held
1.27BCall Options Held
13MPut Options Held
9.79M-
Vanguard Group Inc Valley Forge, PA171MShares$33.7 Billion0.57% of portfolio
-
Black Rock Inc. New York, NY136MShares$26.9 Billion0.54% of portfolio
-
State Street Corp Boston, MA77.8MShares$15.4 Billion0.59% of portfolio
-
Jpmorgan Chase & CO New York, NY53.6MShares$10.6 Billion0.81% of portfolio
-
Capital International Investors Los Angeles, CA38.6MShares$7.62 Billion1.4% of portfolio
About AbbVie Inc.
- Ticker ABBV
- Exchange NYSE
- Sector Healthcare
- Industry Drug Manufacturers—General
- Shares Outstandng 1,768,099,968
- Market Cap $349B
- Description
- AbbVie Inc. discovers, develops, manufactures, and sells pharmaceuticals in the worldwide. The company offers HUMIRA, a therapy administered as an injection for autoimmune and intestinal Behçet's diseases; SKYRIZI to treat moderate to severe plaque psoriasis in adults; RINVOQ, a JAK inhibitor for the treatment of moderate to severe active rheuma...